LewdBear said:
Why are you selectively citing symptoms of Cushing's Syndrome? We're talking about healthy people.
:shock: ?!
You said...,
[/quote]
LewdBear said:
Also, do you not find it slightly weird that this hypothesized 'stress-induced' mild hypercortisolism would be so selective in its symptoms?
Cushing's Syndrome, for example, can cause a moon face, buffalo hump (non-HIV-ARV related lipodystrophy) and purpura.
Why would people under chronic stress not experience mild versions of these symptoms as well?
Then I said...,
They do, you idiolog, I gave you many different, non-'selective' symptoms, moron, take a look, and read the words,
Stress does not have to only have a few selective outputs.
They do, here are a few,
https://health.google.com/health/ref/Cushing+syndrome,
Men may have:
Decreased fertility
Decreased or no desire for sex
Impotence
Other symptoms that may occur with this disease:
Mental changes, such as depression, anxiety, or changes in behavior
Fatigue
Headache
High blood pressure
Increased thirst and urination
These are MILD VERSIONS of your full out "Cushings Symdrome", WHICH PEOPLE UNDER STRESS, WOULD BE SUFFERING FROM, if YOUR IDEA that Cortisol, HAS to be linked to Cushing's symdorme,
What I am telling you, and what everyones mom, and grandmother knows.
stress causes illness, stress is bad, :nono:
OMG REALLY??! NO WAY!!! EVER NOTICED PEOPLE THAT ARE CONSTANTLY STRESSED GET SICK EASIER, ARE ON EDGE, LOSE HAIR?!
Anyone who has any idea about hair loss understands stress can be a cause.
"Oh no, but stress is okay!" "Heart attacks are good for you!"
"Cortisols great!" "Are car keys the same?"
Are you insane?
Go ask your mom, if stress will cause hair loss. WHAT I'M HELPING YOU LEARN, IS INCREASED CORTISOL DOESN'T HAVE TO LEAD TO CUSHING SYNDROME.
THE ACTION OF STRESS, INCREASE CORTISOL,
AMONG OTHER HORMONES, OVER-WORKS THE LIVER AND HEART, AND IS UNHEALTHY IN EXCESS.
Any doctor can EASILY grasp this, and tell you THE SAME THING.
I learned this in elementary school, but you're claiming stress can't hurt people, and can't lead to MANY problems in the body. Are you out of your mind?
What the association is remains unclear. A lot of people have this idea that male pattern baldness is frequently part of a larger syndrome, and I fail to understand why.
Because the health of your hair, is an indicator of overall health in the body, AT LEAST referring to the health of those epithelial cells.
That website appears to let anyone submit an article.
If that is the quality of evidence you plan on producing, I'm through debating with you.
Lol, if you 'being like Bryan' ironically, are going to ignore comments I made back, taking them out of context, then your a waste of air.
What is this, 1984?, an Orwellian nightmare?
I'll tell you when I'm done debating with you.
I asked for references, not a link to your other thread. I'm not concerned with your hypotheses, but rather supporting evidence.
Oh, okay
J Eur Acad Dermatol Venereol. 2009 Jun;23(6):673-7. Epub 2009 Feb 24.
Is androgenetic alopecia a risk for atherosclerosis?
Dogramaci AC, Balci DD, Balci A, Karazincir S, Savas N, Topaloglu C, Yalcin F.
Department of Dermatology, Faculty of Medciine, Mustafa Kemal University, Hatay, Turkey.
catahan85@yahoo.com
BACKGROUND: Several studies have demonstrated the presence of an association between androgenetic alopecia (Androgenetic Alopecia) and cardiovascular disease. The aim of this study was to evaluate subclinical atherosclerosis in patients with Androgenetic Alopecia and healthy controls by the incorporation of carotid intima-media thickness (IMT) and high-sensitive C-reactive protein (hs-CRP) along with echocardiography (ECHO) and exercise electrocardiography (ExECG). METHODS: We performed a case-control study in 50 male patients with Androgenetic Alopecia and 31 age-matched healthy male controls with normal hair status. Both the Androgenetic Alopecia patients and controls with a history of diabetes mellitus, cigarette smoking, hypertension, cardiovascular or cerebrovascular disease, and renal failure were excluded. Androgenetic Alopecia was classified according to the Hamilton-Norwood scale. Serum lipids, serum hs-CRP, total testosterone, and dehydroepiandrosterone sulphate were examined in all study subjects. Carotid ultrasonography was used to measure the IMT of the common carotid arteries (CCA). ECHO and ExECG were performed in all subjects. RESULTS: IMT of the CCA was found to be significantly higher in patients with severe vertex pattern Androgenetic Alopecia when compared to patients with other patterns of Androgenetic Alopecia and healthy controls (P < 0.05). Hs-CRP in patients with any group of Androgenetic Alopecia was not significantly different from those healthy controls (P > 0.05). ECHO showed that cardiac structural and functional measures were in normal ranges. ExECG was also normal in all subjects. CONCLUSION: Severe vertex pattern Androgenetic Alopecia should be considered to have an increased risk of subclinical atherosclerosis. For this reason, CCA IMT measurement can be recommended as a non-invasive and early diagnostic method.
Clin Endocrinol (Oxf). 2009 Oct;71(4):494-9.
Androgenetic alopecia and insulin resistance in young men.
González-González JG, Mancillas-Adame LG, Fernández-Reyes M, Gómez-Flores M, Lavalle-González FJ, Ocampo-Candiani J, Villarreal-Pérez JZ.
Servicio de Endocrinologia, Dr Jose Eleuterio Gonzalez University Hospital, Facultad de Medicina, Universidad Autonoma de Nuevo Leon, Ave. Madero y Gonzalitos S/N, Monterrey, Mexico.
jgonzalezg@fm.uanl.mx
BACKGROUND: Epidemiological studies have associated androgenetic alopecia (Androgenetic Alopecia) with severe young-age coronary artery disease and hypertension, and linked it to insulin resistance. We carried out a case-control study in age- and weight-matched young males to study the link between Androgenetic Alopecia and insulin resistance using the homeostasis model assessment of insulin resistance (HOMA-IR) index or metabolic syndrome clinical manifestations. METHODS: Eighty young males, 18-35 years old, with Androgenetic Alopecia > or = stage III in the Hamilton-Norwood classification, and 80 weight- and age-matched controls were included. Alopecia, glucose, serum insulin, HOMA-IR index, lipid profile and androgen levels, as well as metabolic syndrome criteria, were evaluated. RESULTS: The HOMA-IR index was significantly higher in cases than controls. Nonobese cases had a higher mean diastolic blood pressure and a more frequent family history of Androgenetic Alopecia than nonobese controls. A borderline difference in the HOMA-IR index was found in obese Androgenetic Alopecia cases vs. obese controls [P = 0.055, 95% confidence interval (CI) 2.36-4.20 vs. 1.75-2.73]. Free testosterone values were significantly higher in controls than cases, regardless of body mass index (BMI). A statistically significant additive effect for obesity plus alopecia was found, with significant trends for insulin, the HOMA-IR index, lipids and free testosterone when BMI and alopecia status were used to classify the participants. CONCLUSIONS: Our results support the recommendation for assessing insulin resistance and cardiovascular-related features and disorders in all young males with stage III or higher Androgenetic Alopecia, according to the Hamilton-Norwood classification.
PMID: 19094069 [PubMed - indexed for MEDLINE]
Endocr Regul. 2005 Dec;39(4):127-31.
Premature androgenic alopecia and insulin resistance. Male equivalent of polycystic ovary syndrome?
Starka L, Duskova M, Cermakova I, Vrbiková J, Hill M.
Institute of Endocrinology, Narodni 8, CZ 116 94 Prague 1, Czech Republic.
lstarka@endo.cz
BACKGROUND: Polycystic ovary syndrome (PCOS), the most frequent endocrinopathy in women with estimated prevalence of 5-10 %, is characterised by a hormonal and metabolic imbalance of polygene autosomal trait. The complexity of symptoms and genetic base started up the hypothesis on the existence of male equivalent of PCOS. Precocious loss of hair before 30 years of age was suggested as one of the male symptoms of this syndrome. OBJECTIVES: The aim was to confirm the association of lower levels of follicle stimulating hormone (FSH) and sexual hormone binding globulin (SHBG) or higher free androgen index (FAI) in premature balding men with a reduced insulin sensitivity. PATIENTS/METHODS: The study included 30 men with premature hair loss (defined as grade 3 vertex or more on the alopecia classification scale by Hamilton with Norwood modification) starting before 30 years of age. The hormonal values of the investigated group were compared with those regarded as normal reference values obtained in a group of 256 males in the age of 20-40 years during the Czech population study of iodine deficiency. In all men with premature baldness besides hormonal level determinations insulin tolerance test was carried out. RESULTS: The observed group was divided into two subgroups. The first one showed similar hormonal changes as women with PCOS, namely subnormal SHBG, FSH or increased FAI. The other had either no anomalies in steroid spectrum or only lower SHBG. The groups did not differ either in BMI or in age. The group with hormonal profile resembling that of women with PCOS, showed significantly higher insulin resistance than the group without these changes. CONCLUSIONS: The findings are consistent with the hypothesis that at least a part of the men with premature androgenic alopecia could be considered as a male equivalent of the polycystic ovary syndrome of the women. These premature balding men represent a risk group for the development of impaired glucose tolerance or diabetes mellitus type 2.
Lancet Oncol. 2007 Jan;8(1):21-5.
Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial.
D'Amico AV, Roehrborn CG.
Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Faber Cancer Institute, Boston, MA 02215, USA.
adamico@lroc.harvard.edu
Comment in:
Nat Clin Pract Urol. 2007 Aug;4(8):412-3.
Lancet Oncol. 2007 Feb;8(2):94-5.
Lancet Oncol. 2007 Jan;8(1):4-5.
BACKGROUND: Use of 5 mg/day finasteride (Proscar) for benign prostatic hyperplasia is known to affect serum concentrations of prostate-specific antigen (PSA). When men taking this treatment undergo screening for prostate cancer, a compensatory adjustment of the PSA concentration (to multiply the value by two) is recommended. Whether this recommendation should apply to men taking 1 mg/day finasteride (Propecia) for the treatment of androgenic alopecia is unknown. We aimed to assess the effect of 1 mg/day finasteride on serum PSA in men aged 40-60 years with male-pattern hair loss. METHODS: Between March 13, 1998, and Jan 12, 2000, 355 men aged 40-60 years with male-pattern hair loss were stratified by age decade (40-49 years and 50-60 years), and randomised in a ratio of four to one to 1 mg/day finasteride or placebo. The primary endpoint was the effect of this treatment for 48 weeks on serum PSA concentration compared with placebo. This trial is in the process of being registered on the US National Institutes of Health website . Analyses were according to protocol. FINDINGS: Within 48 weeks of randomisation, men aged 40-49 years and 50-60 years who were assigned 1 mg/day finasteride had a median decrease in serum PSA concentration of 40% (95% CI 34-46) and 50% (44-57), respectively. In men assigned placebo, the median changes were 0% [-14 to 14] and a median increase of 13% [2 to 24], respectively. INTERPRETATION: In men aged 40-60 years, 1 mg/day finasteride for 48 weeks lowers serum PSA concentration. Therefore, the existing recommendation for the adjustment of serum PSA concentration in prostate-cancer screening in men taking 5 mg/day finasteride should also apply to men taking the 1 mg/day preparation for male-pattern hair loss. Research is needed to assess the effect of 1 mg/day finasteride preparation beyond 48 weeks of treatment.
PMID: 17196507 [PubMed - indexed for MEDLINE]
The evidence is over-whelming that these 3 diseases are associated with male pattern baldness.
That's because you accept your about.com reference without question. I don't.
No, you fool, this is common knowledge, if you're going to waste my time with defending stress, then I'm done
educating you.
There is one caveat, however. In some cases there can be something known as "subclinical cushing's" (although this condition is still somewhat controversial.) It means that someone has medically elevated cortisol without other features of Cushing's.
For example this editorial on cortisol and osteoporosis (
http://www.annals.org/content/147/8/I-48.full) :
"219 people referred to 2 medical centers for osteoporosis testing. Most participants were women."
[...]
"Seven apparently healthy people with osteoporosis had high cortisol levels. None of the people without osteoporosis had high levels. All 7 people with high levels had tumors that increased the levels."
That would not constitute 'evidence' of healthy people, with normal cortisol levels, being 'stressed out' to the point of having osteoporosis.
Occult or single symptom conditions with elevated cortisol are therefore excluded.
This study had to do with osteoporosis, I don't care about osteoporosis, at least mine was more prevalent with wound healing.
And this was mainly about women with osteoporosis, wow....
No, the only thing excluded is your mind numbing way of obviously dodging the fact that
stress kills.
Now, I'm done educating you, if you have any more questions if cortisol and stress kills, go ask your doctor or mommy, Shills.